VaxThera

Biotechnology with Purpose

We promote education about vaccines to support informed decision-making in public health.

Health sovereignty with a real impact on people’s lives.

Science that protects lives. Innovation that strengthens the health of all.

We advance health security in Colombia and the region through research and development.

From Colombia, we develop biotechnological solutions for global health challenges.

We innovate today to safeguard the health of tomorrow.

About Us

We are a Colombian biotechnology company that develops products and services to strengthen health sovereignty in Colombia and across the region, positively impacting people's health.

About Us

Ciencia

Investigación

Desarrollo

We focus our efforts on four capabilities to help individuals, families, businesses, and citizens in the region live healthier lives:

Research and development

A team of expert scientists and scientists-in-training is conducting research on emerging, re-emerging, and neglected tropical infectious diseases for the development of new biological products.

Manufacture

Through technology transfer and our own expertise, we have developed capabilities for the fill-finish and production of vaccines using state-of-the-art manufacturing systems: MVA viral vector and mRNA.

Advocacy

Through education and the dissemination of scientific content, work to ensure that populations adopt immunization as a tool for improving public health.

Personalized medicine

We develop innovative health promotion and prevention interventions designed to increase the population's access to vaccines and state-of-the-art therapies.

Our Purpose

VaxThera is a biotechnology company that seeks to transform science, research, and development into benefits that contribute to improving the quality of life in Latin America, while providing the region with the health independence it needs to confront future diseases.

Corporate Governance

Juana Francisca Llano

President, Suramericana

He joined SURA more than 20 years ago, after completing his studies in Law and Political Science. Until 2020, he headed the Insurance Vice Presidency at Suramericana, where he led the acquisition of RSA’s operations in Latin America—a move that resulted in the creation of the corporate office. In April 2020, amidst the global pandemic, he assumed leadership of Suramericana, the corporate entity for Seguros Sura.

Read more Read less

Juan David Escobar Franco

President, Seguros Sura Colombia

Since 2016, Juan David assumed the Presidency of Seguros SURA Colombia. With his leadership, the Company has diversified its portfolio of solutions and transformed the operating model to position itself as a manager of trends and risks, develop new markets in the country and maintain the largest market share of the national insurance industry. In addition, he is a member of the Board of Directors of Bancolombia and the Board of Directors of the Ballet Folklorico de Antioquia.

Read more Read less

Juan Pablo Hernandez Ortiz.

CEO and Founder of VaxThera

He has over 15 years of experience in molecular engineering, focusing on the design of devices for the efficient, high-resolution presentation of long DNA molecules for genomic analysis, as well as the design of devices for early diagnosis. He has an h-index of 22, with 90 scientific articles published in international journals, one book, and 2 patents.

Actualmente es Profesor en el Departamento de Materiales y Nanotecnología de la Universidad Nacional de Colombia en Medellín. También ocupa cargos honorarios en el Departamento de Ingeniería Molecular de la Universidad de Chicago y en el Centro de Biotecnología de la Universidad de Wisconsin-Madison.

Read more Read less

Fil Randazzo

Director general, Leverage Science

A scientist with over 30 years of experience leading science and technology projects—from initial concept to real-world impact—he currently serves as Senior Vice President of Science, Impact, and Special Initiatives at a Seattle-based science and technology fund. His previous roles include serving as Director of Leverage Science, LLC, Deputy Director at the Bill & Melinda Gates Foundation, and Associate Director at Chiron Corporation. He holds a PhD in Molecular, Cellular, and Developmental Biology from Indiana University Bloomington.

Read more Read less

Sue Ann Clemens

Tenured

A globally recognized leader in vaccinology and global health, with over 25 years of experience and contributions to more than 20 life-saving vaccines, including the Oxford/AstraZeneca COVID-19 vaccine. She is currently a professor at Johns Hopkins University and the University of Siena, and a Senior Advisor to the Gates Foundation.

Read more Read less